De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Australian Clinical Labs Toekomstige groei

Future criteriumcontroles 3/6

Australian Clinical Labs zal naar verwachting groeien in winst en omzet met respectievelijk 16.2% en 4.7% per jaar. De winst per aandeel zal naar verwachting groeien met 16.2% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 24.9% zijn.

Belangrijke informatie

16.2%

Groei van de winst

16.2%

Groei van de winst per aandeel

Healthcare winstgroei	25.6%
Inkomstengroei	4.7%
Toekomstig rendement op eigen vermogen	24.9%
Dekking van analisten	Good
Laatst bijgewerkt	26 Sep 2024

Recente toekomstige groei-updates

Recent updates

Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Sep 03

Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today

Aug 14

Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Feb 25

New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)

Dec 22

The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More

Dec 21

The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business

Sep 01

Winst- en omzetgroeiprognoses

ASX:ACL - Toekomstschattingen van analisten en financiële gegevens uit het verleden (AUD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
6/30/2027	804	48	52	185	7
6/30/2026	764	43	48	179	9
6/30/2025	735	37	44	164	8
6/30/2024	696	24	153	160	N/A
3/31/2024	685	20	150	157	N/A
12/31/2023	674	15	147	154	N/A
9/30/2023	686	26	142	149	N/A
6/30/2023	697	36	137	144	N/A
3/31/2023	757	55	143	154	N/A
12/31/2022	818	73	148	165	N/A
9/30/2022	907	126	206	225	N/A
6/30/2022	996	178	263	284	N/A
3/31/2022	931	156	238	256	N/A
12/31/2021	867	134	214	228	N/A
9/30/2021	757	97	179	191	N/A
6/30/2021	647	60	144	154	N/A
3/31/2021	598	79	N/A	N/A	N/A
12/31/2020	549	98	N/A	N/A	N/A
9/30/2020	520	70	N/A	N/A	N/A
6/30/2020	491	41	92	102	N/A
6/30/2019	448	-11	-13	1	N/A
6/30/2018	379	-9	-4	5	N/A
6/30/2017	340	-24	N/A	5	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei ACL ( 16.2% per jaar) ligt boven de spaarquote ( 2.4% ).

Winst versus markt: De winst van ACL ( 16.2% per jaar) zal naar verwachting sneller groeien dan de Australian markt ( 12.2% per jaar).

Hoge groeiwinsten: De winst van ACL zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van ACL ( 4.7% per jaar) zal naar verwachting langzamer groeien dan de markt Australian ( 5.6% per jaar).

Hoge groei-inkomsten: De omzet van ACL ( 4.7% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen ACL zal naar verwachting over 3 jaar hoog zijn ( 24.9 %)

Australian Clinical Labs Toekomstige groei

Future criteriumcontroles 3/6

Belangrijke informatie

Recente toekomstige groei-updates

Australian Clinical Labs Limited Provides Financial Guidance for the Fiscal Year 2025

Consensus EPS estimates fall by 20%

Price target decreased by 7.5% to AU$3.56

Consensus EPS estimates fall by 21%

Price target increased by 7.1% to AU$4.03

Price target decreased by 8.5% to AU$3.76

Recent updates

Australian Clinical Labs Limited to Report Fiscal Year 2025 Results on Aug 26, 2025

Investor sentiment improves as stock rises 25%

Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Should You Think About Buying Australian Clinical Labs Limited (ASX:ACL) Now?

Final dividend of AU$0.09 announced

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Australian Clinical Labs Limited Provides Financial Guidance for the Fiscal Year 2025

Australian Clinical Labs Limited to Report Fiscal Year 2024 Results on Aug 29, 2024

Australian Clinical Labs Limited, Annual General Meeting, Oct 25, 2024

We Think Australian Clinical Labs (ASX:ACL) Is Taking Some Risk With Its Debt

Upcoming dividend of AU$0.03 per share

Consensus EPS estimates fall by 20%

First half dividend reduced to AU$0.03

First half 2024 earnings released: EPS: AU$0.025 (vs AU$0.13 in 1H 2023)

Are Investors Undervaluing Australian Clinical Labs Limited (ASX:ACL) By 46%?

Australian Clinical Labs Limited to Report First Half, 2024 Results on Feb 28, 2024

Is It Time To Consider Buying Australian Clinical Labs Limited (ASX:ACL)?

Price target decreased by 7.5% to AU$3.56

Upcoming dividend of AU$0.07 per share at 4.6% yield

Consensus EPS estimates fall by 21%

Australian Clinical Labs Limited Announces Appointment of Christine Bartlett as Non-Executive Director

Australian Clinical Labs Limited Declares Full Year Fully Franked Dividend for the Fiscal Year 2023, Payable on 3 October 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of AU$0.07 per share at 13% yield

Price target increased by 7.1% to AU$4.03

First half 2023 earnings released: EPS: AU$0.13 (vs AU$0.65 in 1H 2022)

Australian Clinical Labs Limited Announces Dividend for the Six Months Ended December 31, 2022, Payable on April 26, 2023

Investor sentiment improves as stock rises 16%

Price target decreased by 8.5% to AU$3.76

Price target decreased to AU$4.27

High number of new and inexperienced directors

Price target decreased to AU$4.62

Independent Non-Executive Director recently sold AU$71k worth of stock

Australian Clinical Labs Limited Announces Resignation of Dr. Michael Stanford as Non-Executive Director

Australian Clinical Labs Limited, Annual General Meeting, Oct 25, 2023

Independent Non-Executive Director recently sold AU$140k worth of stock

Upcoming dividend of AU$0.41 per share

Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today

Full year 2022 earnings: EPS misses analyst expectations

Price target decreased to AU$5.30

Australian Clinical Labs Limited Declares Dividend for the Period of Six Months Ended 30 June 2022

Investor sentiment deteriorated over the past week

CEO & Executive Director recently bought AU$335k worth of stock

High number of new and inexperienced directors

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Australian Clinical Labs Limited Declares Ordinary Dividend for the Period of Six Months December 31, 2021, Payable April 21, 2022

Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Australian Clinical Labs Limited Revises Earnings Guidance for the First Half 2022

New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)

The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More

Investor sentiment improved over the past week

Consensus EPS estimates increase by 46%

Australian Clinical Labs Limited (ASX:ACL) completed the acquisition of Medlab Pathology Pty Ltd.

Independent Non-Executive Director recently bought AU$99k worth of stock

The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business

Full year 2021 earnings released: EPS AU$0.40 (vs AU$0.28 in FY 2020)

Australian Clinical Labs Limited Provides Earnings Guidance for the Fiscal Year of 2021

Australian Clinical Labs Limited has completed an IPO in the amount of AUD 408.559209 million.

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven